Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation. (31st January 2017)

• Record Type: Journal Article
• Authors: Calvo, Pier Luigi; Serpe, Loredana; Brunati, Andrea; Nonnato, Antonello; Bongioanni, Daniela; Olio, Dominic Dell'; Pinon, Michele; Ferretti, Carlo; Tandoi, Francesco; Carbonaro, Giulia; Salizzoni, Mauro; Amoroso, Antonio; Romagnoli, Renato; Canaparo, Roberto
• Is Part Of: British journal of clinical pharmacology. Volume 83:Number 6(2017:Jun.)
• Page Start: 1252
• Page End: 1262
• Publication Date: 2017-01-31
• Subjects: children -- CYP3A genotyping -- immunosuppression -- liver transplantation -- tacrolimus -- therapeutic drug monitoring; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.13219
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aim: The aim of the present study was to investigate the influence of the cytochrome P450 ( CYP) 3A4/5 genotype in paediatric liver transplant recipients and donors, and the contribution of age and gender to tacrolimus disposition on the first day after transplantation. Methods: The contribution of the CYP3A4/5 genotype in paediatric liver transplant recipients and donors to the tacrolimus blood trough concentrations (C0 ) and the tacrolimus concentration/weight‐adjusted dose ratio on day 1 was evaluated in 67 liver‐transplanted children: 33 boys and 34 girls, mean age 4.5 years. Results: Donor CYP3A5 genotype appears to be significantly associated with tacrolimus disposition on the first day after liver transplantation ( P < 0.0002). Other physiological factors, such as recipient age and donor gender may also play a role and lead to significant differences in tacrolimus C0 and tacrolimus concentration/weight‐adjusted dose ratio on day 1. However, according to the general linear model, only recipient age appears to be independently associated with tacrolimus disposition on the first day after liver transplantation ( P < 0.03). Indeed, there was a faster tacrolimus metabolism in children under 6 years of age ( P < 0.02). Conclusions: Donor CYP3A5 genotype, recipient age and, to a lesser extent, donor gender appear to be associated with tacrolimus disposition on day 1 after transplant. This suggests that increasing the starting tacrolimus doses in paediatric patients under 6 years of age who receive a graft from a male extensive metabolizer may enhance the possibility of their tacrolimus levels reaching the therapeutic range sooner.